An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma
Objective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types. Methods: Consistent with the Program in Ev...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/2/107 |
| _version_ | 1797520743417774080 |
|---|---|
| author | Hal Hirte Xiaomei Yao Sarah E. Ferguson Taymaa May Laurie Elit |
| author_facet | Hal Hirte Xiaomei Yao Sarah E. Ferguson Taymaa May Laurie Elit |
| author_sort | Hal Hirte |
| collection | DOAJ |
| description | Objective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types. Methods: Consistent with the Program in Evidence-based Program’s standardized approach, MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO (the international prospective register of systematic reviews) databases, and four relevant conferences were systematically searched. The Working Group drafted recommendations and revised them based on the comments from internal and external reviewers. Results: We have one recommendation for consolidation therapy and eight recommendations for maintenance therapy. Overall, consolidation therapy with chemotherapy should not be recommended in the target population. For maintenance therapy, we recommended olaparib (Recommendation), niraparib (Weak Recommendation), veliparib (Weak Recommendation), and bevacizumab (Weak Recommendation) for certain patients with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, respectively. We do not recommend some agents as maintenance therapy in four recommendations. We are unable to specify the patient population by histological types for different maintenance therapy recommendations. When new evidence that can impact the recommendations is available, the recommendations will be updated as soon as possible. |
| first_indexed | 2024-03-10T08:00:57Z |
| format | Article |
| id | doaj.art-5dc819e1c4954d9fb1b034885eb72651 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T08:00:57Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-5dc819e1c4954d9fb1b034885eb726512023-11-22T11:26:38ZengMDPI AGCurrent Oncology1198-00521718-77292021-03-012821114112410.3390/curroncol28020107An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal CarcinomaHal Hirte0Xiaomei Yao1Sarah E. Ferguson2Taymaa May3Laurie Elit4Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8S 4L8, CanadaDepartment of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1A1, CanadaDepartment of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1A1, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8S 4L8, CanadaObjective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types. Methods: Consistent with the Program in Evidence-based Program’s standardized approach, MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO (the international prospective register of systematic reviews) databases, and four relevant conferences were systematically searched. The Working Group drafted recommendations and revised them based on the comments from internal and external reviewers. Results: We have one recommendation for consolidation therapy and eight recommendations for maintenance therapy. Overall, consolidation therapy with chemotherapy should not be recommended in the target population. For maintenance therapy, we recommended olaparib (Recommendation), niraparib (Weak Recommendation), veliparib (Weak Recommendation), and bevacizumab (Weak Recommendation) for certain patients with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, respectively. We do not recommend some agents as maintenance therapy in four recommendations. We are unable to specify the patient population by histological types for different maintenance therapy recommendations. When new evidence that can impact the recommendations is available, the recommendations will be updated as soon as possible.https://www.mdpi.com/1718-7729/28/2/107clinical practice guidelineconsolidation therapyevidence-basedmaintenance therapyovarian cancersystemic therapy |
| spellingShingle | Hal Hirte Xiaomei Yao Sarah E. Ferguson Taymaa May Laurie Elit An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma Current Oncology clinical practice guideline consolidation therapy evidence-based maintenance therapy ovarian cancer systemic therapy |
| title | An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma |
| title_full | An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma |
| title_fullStr | An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma |
| title_full_unstemmed | An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma |
| title_short | An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma |
| title_sort | ontario health cancer care ontario clinical practice guideline consolidation or maintenance systemic therapy for newly diagnosed stage ii iii or iv epithelial ovary fallopian tube or primary peritoneal carcinoma |
| topic | clinical practice guideline consolidation therapy evidence-based maintenance therapy ovarian cancer systemic therapy |
| url | https://www.mdpi.com/1718-7729/28/2/107 |
| work_keys_str_mv | AT halhirte anontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT xiaomeiyao anontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT saraheferguson anontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT taymaamay anontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT laurieelit anontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT halhirte ontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT xiaomeiyao ontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT saraheferguson ontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT taymaamay ontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma AT laurieelit ontariohealthcancercareontarioclinicalpracticeguidelineconsolidationormaintenancesystemictherapyfornewlydiagnosedstageiiiiiorivepithelialovaryfallopiantubeorprimaryperitonealcarcinoma |